

Biotech Insights - Fall 2026

By Jeffrey A. Wolfson, Jeffrey Morton, Ph.D., Martin Florman, Daniel S. Dubyak, Chris M. Kang | October 23, 2026

RELATED PRACTICES Life Sciences, Biotechnology, Intellectual Property, Patents, Pharmaceuticals

Welcome to Haynes Boone's Biotech Insights! This newsletter is your go-to resource for staying informed on the latest legal developments in biotechnology. Each edition will feature expert analysis of key topics impacting the biotechnology industry, a spotlight on one of our talented team members and details about where to connect with our team at upcoming industry events. We are committed to keeping you informed in this important and rapidly evolving field. This edition features:

[Hasty Provisional Costs Millions in Lost Revenue: Lessons from Enanta v. Pfizer](#)

In patent preparation practice, a common temptation for some is to cut corners on early filings by providing too low a provisional budget or insufficient time between disclosure and making a filing. Clients frequently push for a quick, low-cost "provisional" patent application to secure an early filing date before a conference presentation, publication or funding round. However, a recent Federal Circuit decision in *Enanta Pharmaceuticals, Inc. v. Pfizer, Inc.* serves as a multimillion-dollar warning: treating provisional applications as mere "quick-and-dirty" placeholders can destroy an otherwise valuable patent portfolio.

[Management Participation in a Sale of Life Science Business Transaction](#)

Management financial participation can be a critical issue when a life science business enters a sale of business transaction. Bonuses and equity arrangements can affect deal economics, retention and the value of the company's scientific and regulatory talent, making early, focused guidance essential. The right approach depends on the details of the business and transaction, and experienced counsel can help identify the issues before they become obstacles.

Read the full [Fall 2026 Biotech Insights here](#).